Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 2,427 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9 % sodium chloride Clear all
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

NCT00711802
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Daptomycin, Standard of Care (SOC)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
1 Year to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 14, 2026, 10:50 AM EDT
Withdrawn Early Phase 1 Interventional

Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation

NCT03330704
View directory record Official record
Conditions
Cerebral Edema, Saline Solution, Hypertonic
Interventions
3% Sodium Chloride, 23.4% Sodium Chloride, 8.4% Sodium Bicarbonate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

NCT05648110
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
3,882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
130
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 14, 2026, 10:50 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty

NCT02341079
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis, Knee, Arthritis, Degenerative, Osteoarthrosis, Osteoarthrosis Deformans
Interventions
Bupivacaine Liposome Injection, Indwelling femoral nerve block
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee

NCT01221441
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
TissueGene-C, Normal Saline
Biological · Drug
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Pinellas Park, Florida • Baltimore, Maryland • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety of Three Intra-articular Injections of Ampion in the Knee of Adults With Osteoarthritis Pain

NCT02184156
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
4 mL injection of Ampion, 4 mL injection of Placebo
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 3 Interventional

Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis

NCT01112722
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Apitox, purified honeybee toxin, lyophilized in saline, histamine
Biological
Lead sponsor
Apimeds, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
Gulf Shores, Alabama • Tucson, Arizona • Garden Grove, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

NCT01023295
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
fosbretabulin, Saline
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

NCT05844527
View directory record Official record
Conditions
Wound of Skin, Abdominal Wound
Interventions
MRG-001, Saline
Drug
Lead sponsor
MedRegen LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 14, 2026, 10:50 AM EDT
Recruiting Phase 4 Interventional

OnabotulinumtoxinA for Trigeminal Neuralgia

NCT06216886
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
OnabotulinumtoxinA 100 UNT [Botox], Sodium Chloride 0.9% for Injection, Preservative Free
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Not applicable Interventional Results available

Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit

NCT02444988
View directory record Official record
Conditions
Critical Illness, Acute Kidney Injury
Interventions
0.9% Saline, Physiologically-balanced isotonic crystalloid
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
5,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Pruritus With Intramuscular Promethazine

NCT04805073
View directory record Official record
Conditions
Pruritus, Pregnancy Related
Interventions
Promethazine, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13, PPSV23, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
14
States / cities
Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

NCT01260727
View directory record Official record
Conditions
HIV Infections
Interventions
PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Not applicable Interventional

Normal Saline Use With Suctioning

NCT02612961
View directory record Official record
Conditions
Tracheostomy
Interventions
3mL of normal saline from the pink sodium chloride bullet, Sham Comparator of 3mL normal saline
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 4 Interventional

Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions

NCT01298973
View directory record Official record
Conditions
Cataracts
Interventions
Viscoat, Saline
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Boynton Beach, Florida • Maitland, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ibuprofen 5% Topical Gel CIPT

NCT01771822
View directory record Official record
Conditions
Pain
Interventions
Ibuprofen 5% topical gel, Topical gel vehicle, Sodium lauryl sulfate 0.2%, Sodium chloride solution 0.9% (saline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Carlstadt, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

Mepo for Eosinophilic Esophagitis (EoE) Study

NCT03656380
View directory record Official record
Conditions
EoE, Eosinophilic Esophagitis
Interventions
Mepolizumab 300 mg, Mepolizumab 100 mg, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

NCT00820846
View directory record Official record
Conditions
HIV Infections
Interventions
pGA2/JS7 DNA vaccine, Placebo, MVA/HIV62 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 14, 2026, 10:50 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Intranasal Lidocaine for Prevention of Postoperative Nausea and Vomiting.

NCT04810494
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
2% Lidocaine HCl topical solution, 0.9% Sodium chloride
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 14, 2026, 10:50 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

NCT04594213
View directory record Official record
Conditions
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Encino, California • Newport Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 14, 2026, 10:50 AM EDT
Withdrawn Phase 2 Interventional

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

NCT00986960
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
repository corticotropin injection, Saline
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 14, 2026, 10:50 AM EDT
Recruiting Phase 3 Interventional

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903
View directory record Official record
Conditions
Transthyretin Amyloidosis With Cardiomyopathy
Interventions
Nucresiran, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
45
States / cities
La Jolla, California • Laguna Hills, California • Stanford, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 14, 2026, 10:50 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

NCT01059786
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Pentostatin, Rituximab, Bendamustine, Acetaminophen, Diphenhydramine, Epinephrine, Antihistamines, Corticosteroids, Bronchodilators, Intravenous (IV) Saline
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 14, 2026, 10:50 AM EDT